CUSIP: 293614103
Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
5,701,341
-
Share change
-
+2,614,131
-
Total reported value
-
$12,545,000
-
Price per share
-
$2.20
-
Number of holders
-
26
-
Value change
-
+$5,967,031
-
Number of buys
-
17
-
Number of sells
-
7
Quarterly Holders Quick Answers
What is CUSIP 293614103?
CUSIP 293614103 identifies ETTX - ENTASIS THERAPEUTICS HLDGS I - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2022
-
Previous quarter:
Q1 2022
Recent filing periods for CUSIP 293614103:
Institutional Holders of ENTASIS THERAPEUTICS HLDGS I - COM (ETTX) as of Q2 2022
As of 30 Jun 2022,
ENTASIS THERAPEUTICS HLDGS I - COM (ETTX) was held by
26 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,701,341 shares.
The largest 10 holders included
GARDNER LEWIS ASSET MANAGEMENT L P, Beryl Capital Management LLC, TPG GP A, LLC, VANGUARD GROUP INC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, DELTEC ASSET MANAGEMENT LLC, Ergoteles LLC, and BRIDGEWAY CAPITAL MANAGEMENT, LLC.
This page lists
26
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.